Myomo Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -84.1% over 5Y.
today you would have $135.41▼ -86.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.91 | $6.44 | $5.01 | $0.51 | $6.84 | $6.73 | $9.03 | $43.20 | $112.50 | |
| P/S | 6.6x | 0.9x | 6.8x | 7.4x | 0.7x | 3.4x | 5.0x | 6.6x | 10.1x | 29.8x |
| P/B | 3.7x | 3.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BSEMBioStem Technologies, Inc. | $3.53 | 4.0x | 2.3x | — | -74.74% | $62.95M |
| SERSerina Therapeutics, Inc. | $2.46 | — | 3.3x | — | -207.94% | $62.49M |
| BOLDBoundless Bio, Inc. | $2.83 | — | 1.0x | — | -67.86% | $64.38M |
| TLPHTalphera Inc | $1.20 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Company description provided by Yahoo Finance.
| 9.0x |
| 15.9x |
| 1.7x |
| 3.1x |
| 3.2x |
| 4.0x |
| 3.8x |
| 3.7x |
| EPS | -$0.37 | -$0.16 | -$0.28 | -$1.52 | -$1.89 | -$3.67 | -$20.79 | -$25.18 | -$87.90 |
| Profit margin | -74.86% | -38.05% | -19.00% | -42.34% | -68.92% | -74.86% | -152.49% | -279.15% | -422.11% | -776.04% |
| ROE | -99.99% | -136.57% | -25.02% | -90.64% | -168.59% | -67.31% | -99.99% | -166.72% | -160.55% | -97.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.3x |
| — |
| -143.36% |
| $62.29M |
| INMBInmune Bio, Inc. | $2.33 | — | 3.2x | — | -74.82% | $64.67M |
| NNOXNano-X Imaging Ltd. | $0.83 | — | 0.5x | — | -50.12% | $65.2M |